Belgium’s National Institute for Radioelements (IRE) and nuclear research centre SCK-CEN have signed an agreement to join efforts on the production of lutetium-177 (Lu-177), a medical radioisotope mainly used to treat prostate cancer.
In a joint statement the two organisations said the use of Lu-177 is one of the most promising approaches to treating prostate cancer.
Currently, the medical radioisotope is used in hospitals to treat neuroendocrine cancers, the statement said.
To read more please visit:
Source: The Independent Nuclear News Agency